Comparative Pharmacology
Head-to-head clinical analysis: FOUNDAYO versus LYNORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOUNDAYO versus LYNORAL.
FOUNDAYO vs LYNORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective progesterone receptor modulator with mixed agonist/antagonist activity on progesterone receptors, primarily antagonistic in the uterus leading to inhibition of endometrial proliferation.
LYNORAL is a progesterone receptor agonist that induces and maintains endometrial changes necessary for pregnancy support. It suppresses gonadotropin secretion, inhibiting ovulation, and alters cervical mucus consistency to impede sperm penetration.
100 mg orally once daily
50 mg orally three times daily
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in healthy adults; prolonged to 6-8 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 12–15 hours (11.2 ± 2.6 h in young adults; 14.8 ± 3.9 h in elderly), requiring once-daily dosing for steady-state within 4–7 days.
Primarily renal (80-90% as unchanged drug), with 10-20% fecal via biliary excretion. Less than 5% metabolized.
Renal: ~50% as unchanged drug; ~20% as glucuronide conjugates. Biliary/fecal: ~30% (including enterohepatic recirculation).
Category C
Category C
Oral contraceptive
Oral contraceptive